Enzymology and toxicity of inorganic arsenic

Arsenic Exposure and Health Effects V

Volumn , Issue , 2003, Pages 225-240

  Vasken Aposhian, H ^a   Zakharyan, Robert A ^a   Healy, Sheila M ^a   Wildfang, Eric ^a   Petrick, Jay S ^a   Sampayo Reyes, Adriana ^a   Board, Philip G ^a   Carter, Dean E ^a   Guha Mazumder, D N ^b   Aposhian, Mary M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Arsenate reductase PNP; Arsenic enzymes of humans; Biotransformation of arsenic; Fate of arsenic; GSH transferase B; MMAIII toxicity

Indexed keywords

ENZYME ACTIVITY; ENZYMES; NUCLEIC ACIDS; PEPTIDES; TOXICITY;

ARSENATE REDUCTASE; DIHYDROLIPOIC ACIDS; GLUTATHIONE S-TRANSFERASES; INORGANIC ARSENATE; METHYLTRANSFERASES; NATURALLY OCCURRING; NUCLEIC ACID METABOLISM; PURINE NUCLEOSIDE PHOSPHORYLASE;

ARSENIC;

EID: 84942626406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451441-7/50018-X     Document Type: Chapter

References (58)

1. Aposhian H.V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 1997, 37:397-419.
2. Aposhian H.V. Environmental justice for children of the poor in developing countries: can we bring it about. Med. Americas 2001, 2:99-102.
3. Aposhian H.V., Zakharyan R.A., Wildfang E.K., Healy S.M., Gailer J., Radabaugh T.R., Bogdan G.M., Powell L.A., Aposhian M.M. How is inorganic arsenic detoxified?. Arsenic Exposure and Health Effects: Proceedings of the Third International Conference on Arsenic Exposure and Health Effects 1999, 289-297. Elsevier Science Ltd, Oxford, UK. W.R. Chappel, C.O. Abermathy, R.L. Calderon (Eds.).
4. III), excreted in human urine. Toxicol. Appl. Pharmacol. 2000, 165:74-83.
5. Aposhian H.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., Yip L., Zakharyan R.A., Maiorino R.M., Dart R.C., Tircus M.G., Gonzalez-Ramirez D., Morgan D.L., Avram D., Aposhian M.M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 2000, 13:693-697.
6. Board P.G., Coggan M., Chelvanayagam G., Easteal S., Jermiin L.S., Schulte G.K., Danley D.E., Hoth L.R., Griffor M.C., Kamath A.V., Rosner M.H., Chrunyk B.A., Perregaux D.E., Gabel C.A., Geoghegan K.F., Pandit J. Indentification, characterization, and crystal structure of the Omega class glutathione transferases. J. Biol. Chem. 2000, 275:24798-24806.
7. Bzowska A., Luic M., Schroeder W., Shugar D., Saenger W., Koellner G. Calf spleen purine nucleoside phosphorylase: purification, sequence and crystal structure of its complex with an N(7)-acycloguanosine inhibitor. FEBS Lett. 1995, 367:214-218.
8. Bzowska A., Kulikowska E., Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol. Ther. 2000, 88:349-425.
9. Chakraborti D., Mohammed M.R., Paul K., Chowdhury U.K., Sengupta M.K., Lodh D., Chanda C.R., Saha K.C., Mukherjee S.C. Arsenic calamity in the Indian subcontinent. What lessons have been learned?. Talanta 2002, 58:3-22.
10. Clapper M.L., Szarka C.E. Glutathione S-transferases: biomarkers of cancer risk and chemopreventive response. Chem.-Biol. Interact. 1998, 377-388.
11. Cohen S.M., Cano M., St.John M.K., Ryder P.C., Uzvolgyi E., Arnold L.L. The carcinogenicity of dimethylarsinic acid (DMA) in rats. Arsenic Exposure and Health Effects IV: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects 2001, 277-283. Elsevier Science Ltd., Oxford, UK. W.R. Chappel, C.O. Abernathy, R.L. Calderon (Eds.).
12. Cullen W.R., McBride B.C., Manji H., Pickett A.W., Reglinski J. The metabolism of methylarsine oxide and sulfide. Appl. Organoment. Chem. 1989, 3:71-78.
13. Delnomdedieu M., Basti M.M., Otvos J.D., Thomas D.J. Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Chem. Biol. Interact. 1994, 90:139-155.
14. Del Razo L.M., Styblo M., Cullen W.R., Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 2001, 174:282-293.
15. Erion M.D., Takabayashi K., Smith H.B., Kessi J., Wagner S., Honger S., Shames S.L., Ealick S.E. Purine nucleoside phosphorylase. 1. Structure-function studies. Biochemistry 1997, 36:11725-11734.
16. Gailer J.G., George G.N., Pickering I.J., Prince R.C., Ringwald S.C., Pemberton J.E., Glass R.S., Younis H.S., DeYoung W., Aposhian H.V. A metabolic link between arsenite and selenite: the seleno-bis (S-glutathionyl) arsinium ion. J. Am. Chem. Soc. 2000, 122:4637-4639.
17. Gregus Z., Németi B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 2002, 70:13-19.
18. Gregus Z., Gyurasics A., Csanaky I. Biliary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats. Toxicol. Sci. 2000, 56:18-25.
19. Hayes J.D., Strange R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000, 61:154-166.
20. Healy S.M., Zakharyan R.A., Aposhian H.V. Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat. Res. 1997, 386:229-239.
21. Healy S.M., Casarez E.A., Ayala-Fierro F., Aposhian H.V. Enzymatic methylation of arsenic compounds. Toxicol. Appl. Pharmacol. 1998, 148:65-70.
22. Kline P.C., Schramm V.L. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry 1993, 32:13212-13219.
23. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 2000, 72:5172-5177.
24. Le X.C., Ma M., Lu X., Cullen W.R., Aposhian H.V., Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 2000, 108:1015-1018.
25. Lin S., Shi Q., Nix B., Styblo M., Beck M., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., Thomas D.J. A novel S-adenosyl-l-methionine: arsenic (III) methyltransferase from a rat liver cytosol. J. Biol. Chem. 2002, 277:10795-10803.
26. Liu J., Zheng B., Aposhian H.V., Zhou Y., Chen M.-L., Waalkes M.P. Chronic arsenic poisoning from burning high arsenic containing coal in Guiazhou, China. Environ. Health Perspect. 2002, 110:119-122.
27. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl Acad. Sci. USA 2002, 99:6053-6058.
28. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 1991, 3:45-81.
29. Montgomery J.A., Niwas S., Rose J.D., Secrist J.A., Babu Y.S., Bugg C., Erion M.D., Guida W.C., Ealick S.E. Structure-based design of inhibitors of purine nucleoside phosphorylase. 1.9-(arylmethyl) derivatives of 9-deazaguanine. J. Med. Chem. 1993, 36:55-69.
30. Németi B., Gregus Z. Reduction of arsenate to arsenite in hepatic cytosol. Toxicol. Sci. 2002, 70:4-12.
31. Nordstrom D.K. Worldwide occurrences of arsenic in ground water. Science 2002, 296:2143-2145.
32. Parks R.E., Agarwall R.P. Purine nucleoside phosphorylase. Methods Enzymol. 1972, 51:483-514.
33. Parks R.E., Stoeckler J.D., Cambor C., Savarese T.M., Crabtree G.W., Chu S.H. Molecular Actions and Targets for Cancer Chemotherapeutic Agents 1981, 229-252. Academic Press, New York. A. Sartorelli, J.S. Lazo, J.R. Bertino (Eds.).
34. III) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 2000, 163:203-207.
35. 50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 2001, 14:651-656.
36. Radabaugh T.R., Aposhian H.V. Enzymatic reduction of arsenic compounds in mammalian systems: reduction of arsenate to arsenite by human liver arsenate reductase. Chem. Res. Toxicol. 2000, 13:26-30.
37. Radabaugh T.R., Sampayo-Reyes A., Zakharyan R.A., Aposhian H.V. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 2002, 15:692-698.
38. Rossman T.G., Visalli M.A., Uddin A.N., Hu Y. Human cell models for arsenic carcinogenicity and toxicity: transformation and genetic susceptibility. Arsenic Exposure and Health Effects IV: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects 2001, 285-295. Elsevier Science Ltd, Oxford, UK. W.R. Chappel, C.O. Abernathy, R.L. Calderon (Eds.).
39. Salinas A.E., Wong M.G. Glutathione S-transferase. Curr. Med. Chem. 1999, 6:279-309.
40. Sampayo-Reyes A., Zakharyan R.A., Healy S.M., Aposhian H.V. Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Chem. Res. Toxicol. 2000, 13:1181-1186.
41. Scott N., Hatlelid K.M., MacKenzie N.E., Carter D.E. Reactions of arsenic (III) and arsenic (V) species with glutathione. Chem. Res. Toxicol. 1993, 6:102-106.
42. Skerfving S. Biological monitoring of exposure to inorganic lead. Biological Monitoring of Toxic Metals 1986, 169-197. Plenum Press, New York. T.W. Clarkson, L. Friberg, G.F. Nordberg, P.R. Sager (Eds.).
43. Stoeckler J.D. Developments in Cancer Chemotherapy 1984, 35-60. CRC Press, Boca Raton, FL. R.J. Glazer (Ed.).
44. Strange R.C., Jones P.W., Fryer A.A. Glutathione S transferase: genetics and role in toxicology. Toxicol. Lett. 2000, 112-113.
45. Strange R.C., Jones P.W., Fryer A.A. Glutathione S transferase: genetics and role in toxicilogy. Toxicol. Lett. 2000, 357-363.
46. Styblo M., Serves S.V., Cullen W.R., Thomas D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 1997, 10:27-33.
47. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 2000, 74:289-299.
48. Styblo M., Drobna Z., Jaspers I., Lin S., Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect. 2002, 110:767-771.
49. 74As-arsenite. Arch. Toxicol. 1982, 51:65-77.
50. Vahter M., Couch R., Nermell B., Nilsson R. Lack of methylation of inorganic arsenic in the chimpanzee. Toxicol. Appl. Pharmacol. 1995, 133:262-268.
51. Waalkes M.P., Keefer L.K., Diwan B.A. Induction of proliferative lesions of the uterus, testes and liver in Swiss mice given repeated injections of sodium arsenate. Arsenic Exposure and Health Effects IV: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects 2001, 255-264. Elsevier Science Ltd, Oxford, UK. W.R. Chappel, C.O. Abernathy, R.L. Calderon (Eds.).
52. Wildfang E., Radabaugh T.R., Aposhian H.V. Enzymatic methylation of arsenic compounds. IX. Liver arsenite methyltransferase and arsenate reductase activities in primates. Toxicology 2001, 168:213-221.
53. Williams S.R., Goddard J.M., Martin D.W. Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res. 1984, 12:5779-5787.
54. V reductase. Chem. Res. Toxicol. 1999, 12:1278-1283.
55. Zakharyan R.A., Wu Y., Bogdan G.M., Aposhian H.V. Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem. Res. Toxicol. 1995, 8:1029-1038.
56. Zakharyan R.A., Wildfang E., Aposhian H.V. Enzymatic methylation of arsenic compounds: III. The marmoset and tamarin, but not the rhesus, monkey are deficient in methyltransferase that methylate inorganic arsenic. Toxicol. Appl. Pharmacol. 1996, 140:77-84.
57. III) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes. Toxicol. Appl. Pharmacol. 1999, 158:9-15.
58. V) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 2001, 14:1051-1057.